相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Hepatitis B surface antibody titres and hepatitis B reactivation with direct-acting antiviral therapy for hepatitis C
Shiva Poola et al.
JOURNAL OF VIRAL HEPATITIS (2021)
Persistent augmentation of central arterial stiffness following viral clearance by direct-acting antivirals in chronic hepatitis C
Ju-Yi Chen et al.
JOURNAL OF VIRAL HEPATITIS (2021)
Hepatitis C Virus Cure Rates Are Reduced in Patients With Active but Not Inactive Hepatocellular Carcinoma: A Practice Implication
Eiichi Ogawa et al.
CLINICAL INFECTIOUS DISEASES (2020)
Patient-centered outreach treatment toward micro-elimination of hepatitis C virus infection in hemodialysis patients
Chung-Feng Huang et al.
KIDNEY INTERNATIONAL (2020)
Hepatitis C Virus Clearance by Direct-Acting Antivirals Agents Improves Endothelial Dysfunction and Subclinical Atherosclerosis: HEPCAR Study
Rocío Muñoz-Hernández et al.
Clinical and Translational Gastroenterology (2020)
Hepatic benefits of HCV cure
Vincenza Calvaruso et al.
JOURNAL OF HEPATOLOGY (2020)
Beneficial effects of DAAs on cardiac function and structure in hepatitis C patients with low-moderate liver fibrosis
Andrea Dalbeni et al.
JOURNAL OF VIRAL HEPATITIS (2020)
Lymphocyte Landscape after Chronic Hepatitis C Virus (HCV) Cure: The New Normal
Alip Ghosh et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Emerging resistance to directly-acting antiviral therapy in treatment of chronic Hepatitis C infection-A brief review of literature
Mohit Bhatia et al.
JOURNAL OF FAMILY MEDICINE AND PRIMARY CARE (2020)
Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals
Andrea Casadei Gardini et al.
DIGESTIVE AND LIVER DISEASE (2019)
Immunological recovery in T-cell activation after sustained virologic response among HIV positive and HIV negative chronic Hepatitis C patients
Benjamin Emmanuel et al.
HEPATOLOGY INTERNATIONAL (2019)
Direct-acting antiviral treatment for hepatitis C
Jacinta A. Holmes et al.
LANCET (2019)
Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study
Fabrice Carrat et al.
LANCET (2019)
Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis
Fanpu Ji et al.
JOURNAL OF HEPATOLOGY (2019)
Persistent gamma delta T-cell dysfunction in chronic HCV infection despite direct-acting antiviral therapy induced cure
Alip Ghosh et al.
JOURNAL OF VIRAL HEPATITIS (2019)
Peripheral PD-1+ T Cells Co-expressing Inhibitory Receptors Predict SVR With Ultra Short Duration DAA Therapy in HCV Infection
Sara Romani et al.
FRONTIERS IN IMMUNOLOGY (2019)
Recovery of metabolic impairment in patients who cleared chronic hepatitis C infection after direct-acting antiviral therapy
Simone Lanini et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
Sustained virological response does not improve long-term glycaemic control in patients with type 2 diabetes and chronic hepatitis C
Jia Li et al.
LIVER INTERNATIONAL (2019)
Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial
Lai Wei et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)
Treatment of Chronic Hepatitis C: Efficacy, Side Effects and Complications
Lisa Sandmann et al.
VISCERAL MEDICINE (2019)
HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals
V. Calvaruso et al.
JOURNAL OF VIRAL HEPATITIS (2018)
Systematic review with meta-analysis: recurrence of hepatocellular carcinoma following direct-acting antiviral therapy
N. Saraiya et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection
Omar El-Sherif et al.
GASTROENTEROLOGY (2018)
Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs
Pierre Nahon et al.
GASTROENTEROLOGY (2018)
Liver Angiopoietin-2 Is a Key Predictor of De Novo or Recurrent Hepatocellular Cancer After Hepatitis C Virus Direct-Acting Antivirals
Francesca Faillaci et al.
HEPATOLOGY (2018)
Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry
Luca Saverio Belli et al.
JOURNAL OF HEPATOLOGY (2018)
Recovery of hepatitis C specific T-cell responses after rituximab therapy in hepatitis C mixed cryoglobulinemic vasculitis
Poonam Mathur et al.
JOURNAL OF MEDICAL VIROLOGY (2018)
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection
S. Zeuzem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Impact of Direct Acting Antiviral (DAA) Treatment on Glucose Metabolism and Reduction of Pre-diabetes in Patients with Chronic Hepatitis C
Philip Weidner et al.
JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES (2018)
Updates in the management and treatment of HCV genotype 3, what are the remaining challenges?
Jee-Fu Huang et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2018)
Multitarget Direct-Acting Antiviral Therapy Is Associated With Superior Immunologic Recovery in Patients Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus
Shikha Shrivastava et al.
HEPATOLOGY COMMUNICATIONS (2018)
Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes
Zobair M. Younossi et al.
CLINICAL INFECTIOUS DISEASES (2018)
Oral direct-acting antivirals and the incidence or recurrence of hepatocellular carcinoma: a systematic review and meta-analysis
Sonal Singh et al.
FRONTLINE GASTROENTEROLOGY (2018)
Worsening of Serum Lipid Profile after Direct Acting Antiviral Treatment
Stefano Gitto et al.
ANNALS OF HEPATOLOGY (2018)
Long-term persistence of HCV NS5A resistance-associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir
David Wyles et al.
ANTIVIRAL THERAPY (2018)
Effect of antiviral therapy for HCV on lipid levels
Stefan Mauss et al.
ANTIVIRAL THERAPY (2017)
Spontaneous remission of hepatitis B virus reactivation during direct-acting antiviral agent-based therapy for chronic hepatitis C
Ken Sato et al.
HEPATOLOGY RESEARCH (2017)
Hepatitis B virus reactivation among hepatitis C patients treated with directacting antiviral therapies in routine clinical practice
Elisabetta Loggi et al.
JOURNAL OF CLINICAL VIROLOGY (2017)
Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression
Reem Waziry et al.
JOURNAL OF HEPATOLOGY (2017)
Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals
Stacey B. Prenner et al.
JOURNAL OF HEPATOLOGY (2017)
Improvement of glycemic state among responders to Sofosbuvir-based treatment regimens: Single center experience
Shereen Abdel Alem et al.
JOURNAL OF MEDICAL VIROLOGY (2017)
Augmentation of hepatitis C virus-specific immunity and sustained virologic response
S. Shrivastava et al.
JOURNAL OF VIRAL HEPATITIS (2017)
International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates
Norah A. Terrault et al.
TRANSPLANTATION (2017)
Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma
Kenji Ikeda et al.
DIGESTIVE DISEASES AND SCIENCES (2017)
Current therapy for chronic hepatitis C: The role of direct-acting antivirals
Guangdi Li et al.
ANTIVIRAL RESEARCH (2017)
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
Sarah Blach et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2017)
Reactivation of hepatitis B virus during interferon-free therapy with daclatasvir and asunaprevir in patient with hepatitis B virus/hepatitis C virus co-infection
Hiroki Takayama et al.
HEPATOLOGY RESEARCH (2016)
Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis
Bryony Simmons et al.
CLINICAL INFECTIOUS DISEASES (2016)
Rapid decline of fasting glucose in HCV diabetic patients treated with direct-acting antiviral agents
P. Pavone et al.
CLINICAL MICROBIOLOGY AND INFECTION (2016)
Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens
Jean-Michel Pawlotsky
GASTROENTEROLOGY (2016)
Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge
Anne De Monte et al.
JOURNAL OF CLINICAL VIROLOGY (2016)
Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals
Fabio Conti et al.
JOURNAL OF HEPATOLOGY (2016)
Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin
Zobair M. Younossi et al.
JOURNAL OF HEPATOLOGY (2016)
Reversion of disease manifestations after HCV eradication
Adriaan J. van der Meer et al.
JOURNAL OF HEPATOLOGY (2016)
Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment
Karin Kozbial et al.
JOURNAL OF HEPATOLOGY (2016)
Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy
Maria Reig et al.
JOURNAL OF HEPATOLOGY (2016)
Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts
JOURNAL OF HEPATOLOGY (2016)
Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial
Michael Manns et al.
LANCET INFECTIOUS DISEASES (2016)
DAAs Rapidly Reduce Inflammation but Increase Serum VEGF Level: A Rationale for Tumor Risk during Anti-HCV Treatment
Rosanna Villani et al.
PLOS ONE (2016)
Rapid Increase in Serum Low-Density Lipoprotein Cholesterol Concentration during Hepatitis C Interferon-Free Treatment
Satoru Hashimoto et al.
PLOS ONE (2016)
A case of acute hepatitis B in a chronic hepatitis C patient after daclatasvir and asunaprevir combination therapy: hepatitis B virus reactivation or acute self-limited hepatitis?
Kazuhiko Hayashi et al.
CLINICAL JOURNAL OF GASTROENTEROLOGY (2016)
Hepatitis B Virus Reactivation During Successful Treatment of Hepatitis C Virus With Sofosbuvir and Simeprevir
Jeffrey M. Collins et al.
CLINICAL INFECTIOUS DISEASES (2015)
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease
Michael Charlton et al.
GASTROENTEROLOGY (2015)
Effect of Sofosbuvir and Ribavirin Treatment on Peripheral and Hepatic Lipid Metabolism in Chronic Hepatitis C Virus, Genotype 1-Infected Patients
Eric G. Meissner et al.
HEPATOLOGY (2015)
Ledipasvir/sofosbuvir treatment of hepatitis C virus is associated with reduction in serum apolipoprotein levels
Z. M. Younossi et al.
JOURNAL OF VIRAL HEPATITIS (2015)
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis
M. P. Curry et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
G. R. Foster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Roles of Lipoproteins and Apolipoproteins in Particle Formation of Hepatitis C Virus
Takasuke Fukuhara et al.
TRENDS IN MICROBIOLOGY (2015)
Diabetes and hepatitis C: a two-way association
Sara Salehi Hammerstad et al.
FRONTIERS IN ENDOCRINOLOGY (2015)
Assessing cardiovascular risk in hepatitis C: An unmet need
Javier Ampuero et al.
WORLD JOURNAL OF HEPATOLOGY (2015)
Infrequent Development of Resistance in Genotype 1-6 Hepatitis C Virus-Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials
Evguenia S. Svarovskaia et al.
CLINICAL INFECTIOUS DISEASES (2014)
Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents
Vincenza Conteduca et al.
JOURNAL OF INFECTION (2014)
Hepatitis B virus and hepatitis C virus dual infection
Gaia Caccamo et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Hepatitis C Virus, Cholesterol and Lipoproteins - Impact for the Viral Life Cycle and Pathogenesis of Liver Disease
Daniel J. Felmlee et al.
VIRUSES-BASEL (2013)
Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents
F. Poordad et al.
JOURNAL OF VIRAL HEPATITIS (2012)
Treatment Failure and Resistance with Direct-Acting Antiviral Drugs Against Hepatitis C Virus
Jean-Michel Pawlotsky
HEPATOLOGY (2011)
Hepatitis C Virus Infection Promotes Hepatic Gluconeogenesis through an NS5A-Mediated, FoxO1-Dependent Pathway
Lin Deng et al.
JOURNAL OF VIROLOGY (2011)
Hepatitis C virus hijacks host lipid metabolism
Gulam H. Syed et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2010)
Redefining Chronic Viral Infection
Herbert W. Virgin et al.
CELL (2009)
Reactivation of Hepatitis B
Jay H. Hoofnagle
HEPATOLOGY (2009)
HCV replication suppresses cellular glucose uptake through down-regulation of cell surface expression of glucose transporters
Daisuke Kasai et al.
JOURNAL OF HEPATOLOGY (2009)
Reliance of host cholesterol metabolic pathways for the life cycle of hepatitis C virus
Jin Ye
PLOS PATHOGENS (2007)
分享论文
